The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10520 malaria professionals are enjoying the free benefits of MalariaWorld today

chloroquine

Absence of Association between Piperaquine In Vitro Responses and Polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe Genes in Plasmodium falciparum

August 18, 2010 - 12:43 -- Kabogo Ndegwa
Author(s): 
Sébastien Briolant, Maud Henry, Claude Oeuvray, Rémy Amalvict, Eric Baret, Eric Didillon, Christophe Rogier, and Bruno Pradines
Reference: 
Antimicrobial Agents and Chemotherapy, September 2010, p. 3537-3544, Vol. 54, No. 9

We have analyzed the profiles of 23 of Plasmodium falciparum strains for their in vitro chemosusceptibilities to piperaquine (PPQ), dihydroartemisinin (DHA), chloroquine, monodesethylamodiaquine, quinine, mefloquine, lumefantrine, atovaquone, pyrimethamine, and doxycycline (DOX) in association with polymorphisms in genes involved in quinoline resistance (Plasmodium falciparum crt [pfcrt], pfmdr1, pfmrp, and pfnhe).

Medical Condition: 

Review: Changes in the burden of malaria in sub-Saharan Africa

July 29, 2010 - 10:38 -- Patrick Sampao
Author(s): 
Wendy Prudhomme O'Meara, Judith Nekesa Mangeni, Rick Steketee, Brian Greenwood
Reference: 
The Lancet Infectious Diseases, Volume 10, Issue 8, August 2010, Pages 545-555

To assess the contribution of specific malaria interventions and other general factors in bringing about these changes, we reviewed studies that have reported recent changes in the incidence or prevalence of malaria in sub-Saharan Africa.

Continent: 
Region: 
Medical Condition: 
Medical Treatment: 

Short Communication: Purified Plasmodium falciparum multi-drug resistance protein (PfMDR 1) binds a high affinity chloroquine analogue

July 19, 2010 - 12:01 -- Patrick Sampao
Author(s): 
Perri Pleeter, Jacqueline K. Lekostaj, Paul D. Roepe
Reference: 
Molecular and Biochemical Parasitology, Volume 173, Issue 2, October 2010, Pages 158-161

We utilize the recent successful overexpression of recombinant Plasmodium falciparum multi-drug resistance transporter, purification and reconstitution of the protein, and a novel high affinity chloroquine analogue to probe hypothesized interaction between the transporter and quinoline drugs.

Medical Condition: 

Invited Review: Quinolines and structurally related heterocycles as antimalarials

June 14, 2010 - 12:53 -- Kabogo Ndegwa
Author(s): 
Kirandeep Kaur, Meenakshi Jain, Ravi P. Reddy, Rahul Jain
Reference: 
European Journal of Medicinal Chemistry, Volume 45, Issue 8, August 2010, Pages 3245-3264

The quinoline scaffold is prevalent in a variety of pharmacologically active synthetic and natural compounds. The discovery of chloroquine, the most famous drug containing this scaffold resulted in control and eradication of malaria for decades. The other known antimalarial drugs from the quinoline family include: quinine, amodiaquine, piperaquine, primaquine, and mefloquine.

Synergy of mefloquine activity with atorvastatin, but not chloroquine and monodesethylamodiaquine, and association with the pfmdr1 gene

June 10, 2010 - 12:48 -- Patrick Sampao
Author(s): 
Nathalie W., Sébastien B., et al.
Reference: 
J. Antimicrob. Chemother., July 2010; 65: 1387 - 1394.

The aim of the study was to assess the in vitro potentiating effects of atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, in combination with mefloquine, chloroquine or monodesethylamodiaquine against Plasmodium falciparum and to evaluate whether the effects of atorvastatin could be associated with mutations or gene copy number in multidrug resistance (MDR)-like protein genes.

Medical Condition: 

Empowering malaria vaccination by drug administration

June 8, 2010 - 09:50 -- Kabogo Ndegwa
Author(s): 
Robert W Sauerwein, Else M Bijker, Thomas L Richie
Reference: 
Current Opinion in Immunology, Volume 22, Issue 3, June 2010, Pages 367-373

Although significant progress has been made in clinical development, a protective malaria vaccine remains elusive. Here we review some of the immune subversive mechanisms used by the Plasmodium malaria parasite and propose a potentially effective strategy to achieve complete protection that may serve as a blue print for clinical usage.

Medical Condition: 
Medical Treatment: 

Synthesis of 2-[3-(7-Chloro-quinolin-4-ylamino)-alkyl]-1-(substituted phenyl)-2,3,4,9-tetrahydro-1H-β-carbolines as a new class of antimalarial agents

May 28, 2010 - 10:02 -- Kabogo Ndegwa
Author(s): 
Leena Gupta, Kumkum Srivastava, Shubhra Singh, S.K. Puri, Prem M.S. Chauhan
Reference: 
Bioorganic & Medicinal Chemistry Letters, Volume 18, Issue 11, 1 June 2008, Pages 3306-3309

A series of hybrid molecules 2-[3-(7-Chloro-quinolin-4-ylamino)-alkyl]-1-(substituted phenyl)-2,3,4,9-tetrahydro-1H-β-carbolines have been synthesized and screened for their in vitro antimalarial activity against chloroquine-sensitive strains of Plasmodium falciparum.

Medical Condition: 

Open Access | Methodology: Rapid identification of chloroquine and atovaquone drug resistance in Plasmodium falciparum using high-resolution melt polymerase chain reaction

May 24, 2010 - 13:02 -- Kabogo Ndegwa
Author(s): 
Gan L, Loh J
Reference: 
Malaria Journal 2010, 9:134 (21 May 2010)

PCR-HRM is an inexpensive option for the determination of drug resistance profile in P. falciparum and will see increasing use as an alternative to sequencing and 5'nuclease PCR assays in reference laboratories or once PCR systems that are able to conduct HRM become commonplace.

Technology: 
Medical Treatment: 

Moandaensine, a dimeric indole alkaloid from Strychnos moandaensis (Loganiaceae)

May 13, 2010 - 13:30 -- Patrick Sampao
Author(s): 
Robert V., Michel F., et al.
Reference: 
Phytochemistry Letters, Volume 3, Issue 2, 11 June 2010, Pages 100-103

The chemical investigation of the liana Strychnos moandaensis De Wild. led to the isolation of moandaensine, a novel dimeric indole alkaloid.

Medical Condition: 

Open Access | Reliability of Antimalarial Sensitivity Tests Depends on Drug Mechanisms of Action

May 6, 2010 - 07:23 -- Patrick Sampao
Author(s): 
Sharon Wein, Marjorie Maynadier, Christophe Tran Van Ba, Rachel Cerdan, Suzanne Peyrottes, Laurent Fraisse, and Henri Vial
Reference: 
J. Clin. Microbiol., May 2010; 48: 1651 - 1660.

Our results suggest some minimal conditions to apply these tests that should give rise to a standard 50% inhibitory concentration, regardless of the mechanism of action of the compounds, and highlight that the most commonly used in vitro antimalarial activity tests do not have the same potential.

Technology: 
Medical Condition: 

Pages

Subscribe to RSS - chloroquine